

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Review Proposal Project (RPP)

#### NICE Technology Appraisal No.245; Apixaban for the prevention of venous thromboembolic events in the knee and hip

#### Provisional matrix of consultees and commentators

| Consultees  | Commentators (no right to submit or appeal)   |
|---|---|
| <p><u>Companies</u></p> <ul style="list-style-type: none"> <li>• Bristol Myers Squibb and Pfizer (apixaban)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Anticoagulation Europe</li> <li>• Black Health Agency</li> <li>• British Lung Foundation</li> <li>• Equalities National Council</li> <li>• Lifeblood: The Thrombosis Charity</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Anticoagulation Specialist Association</li> <li>• Association of Anaesthetists</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Cardiovascular Society</li> <li>• British Geriatrics Society</li> <li>• British Orthopaedic Association</li> <li>• British Society for Haematology</li> <li>• British Society for Haemostasis and Thrombosis</li> <li>• British Thoracic Society</li> <li>• British Vein Institute</li> <li>• Clinical Leaders of Thrombosis</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Surgeons</li> </ul> | <p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British Cardiovascular Industry Association</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Bayer (rivaroxaban)</li> <li>• Boehringer Ingelheim (dabigatran etexilate)</li> <li>• GlaxoSmithKline (fondaparinux)</li> <li>• Leo Pharma (tinzaparin sodium)</li> <li>• Pfizer (dalteparin sodium)</li> <li>• Sanofi (enoxaparin sodium)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Antithrombotic Trialists' (ATT) Collaboration</li> <li>• Cochrane Peripheral Vascular Disease Group</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> |

## Appendix A

| <b>Consultees</b>   | <b>Commentators (no right to submit or appeal)</b>  |
|---|---|
| <ul style="list-style-type: none"> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society of Vascular Nurses</li> <li>• Society for Vascular Technology</li> <li>• UK Clinical Pharmacy Association</li> <li>• Vascular Society of Great Britain and Ireland</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS South Worcestershire</li> <li>• NHS Tower Hamlets</li> <li>• Welsh Government</li> </ul> | <ul style="list-style-type: none"> <li>• Thrombosis Research Institute</li> <li>• Wellcome Trust</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guidelines Centre</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul> |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that manufacture comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing company evidence submission to the Institute.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.